The DOI matches its Crossref record.
Combination therapy with octreotide and α-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors
Abstract
OBJECTIVE: We investigated the antiproliferative efficacy of the addition of alpha-interferon to the somatostatin analogue octreotide in patients with metastasized gastroenteropancreatic tumors unresponsive to octreotide monotherapy. METHODS: In an open prospective trial, 21 patients with metastasized neuroendocrine gastroenteropancreatic tumors (nine patients with carcinoid syndrome, eight with nonfunctioning tumors, four with gastrinoma) were treated with 5 x 10(6) IU alpha-interferon tiw in addition to 200 microg of octreotide tid. All patients, including 16 patients with preceding monotherapy with 200 microg of octreotide tid, had tumor progression documented by computed tomography before entering the study. Growth response (computed tomography documented) and biochemical response were assessed at 3-month intervals. RESULTS: Inhibition of tumor growth was observed in 14 patients (67%), 11 of whom had preceding octreotide monotherapy; complete regression was observed in one patient lasting for 49 months and stable disease (stand-still) in 13 patients lasting for 3 to 52 months (median, 12 months). Seven patients failing this combination therapy exhibited a significantly shorter overall survival (median, 23 months; range, 5 to 42 months) than the 14 patients responding to this regimen (median, 68 months; range, 12 to 112 months; p = 0.007). Two patients are still alive. Biochemical response was achieved in 69% of patients with functioning tumors: in three of four patients with gastrinoma and in six of nine patients with carcinoid syndrome. CONCLUSIONS: These data suggest that the addition of alpha-interferon to octreotide has antiproliferative efficacy in a subgroup of patients with advanced metastatic disease unresponsive to octreotide monotherapy. Prolonged survival was seen in the responder group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Faiss, S., Pape, U.-F., Böhmig, M., Dörffel, Y., Mansmann, U., Golder, W., Riecken, E. O., & Wiedenmann, B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.142 · Cited by 501
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours
Plöckinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E. P., de Herder, W. W., Goede, A., Caplin, M., Öberg, K., Reubi, J. C., et al. (2004) · Neuroendocrinology · doi:10.1159/000085237 · Cited by 477
Metadata
- Authors
- Frank, M.
- Venue
- The American Journal of Gastroenterology
- Published
- 1999-05
- Volume
- 94
- Issue
- 5
- Pages
- 1381-1387
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2029833280
- Cited by
- 191
- References
- 0
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination therapy with octreotide and α-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. https://app.cochat.ai/papers/10.1016/s0002-9270(99)00146-x
- The paper
- Frank, M. (1999). Combination therapy with octreotide and α-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. The American Journal of Gastroenterology. https://doi.org/10.1016/s0002-9270(99)00146-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.